Lexeo Therapeutics, a clinical-stage genetic-medicine company based in New York, is planning to make its debut on the Nasdaq Global Market under the ticker NASDAQ:LXEO. The firm's initial public offering (IPO) aims to offer 9 million shares priced between $13 and $15 each, with an expectation of netting approximately $112.9 million at a midpoint price of $14 per share.
Should underwriters opt to purchase an additional 1.35 million shares, the total proceeds from the IPO could potentially reach up to $130.5 million. This capital is intended to support Lexeo's clinical development activities and is projected to fund operations until Q2 2026.
Upon completion of the IPO, Lexeo estimates it will have roughly 26 million shares outstanding. This would result in a market capitalization exceeding $364 million at the midpoint price, marking a significant step for the firm in its journey to advance genetic medicine.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.